menu

Medical Program: Locally advanced prostate cancer, muscle-invasive bladder cancer

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

TAR-210 vs Intravesical Chemotherapy in Intermediate-Risk Non–Muscle-Invasive Bladder Cancer With Susceptible FGFR Alterations: MoonRISe-1 

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Comments
  • Overview

    MoonRISe-1: Phase 3 study of TAR-210, an erdafitinib intravesical delivery system, versus intravesical chemotherapy in patients with intermediate-risk non–muscle-invasive bladder cancer with susceptible FGFR alterations.

    Advancements in genitourinary cancers are evolving rapidly, and it is often challenging for busy urologists and urologic oncologists to stay current with these emerging data, which can lead to suboptimal outcomes in their patients. In this activity, expert faculty assess key data in locally advanced prostate cancer and bladder cancer and best practices for the integration of these findings to clinical practice.

Facebook Comments

Recommended
Details
Comments
  • Overview

    MoonRISe-1: Phase 3 study of TAR-210, an erdafitinib intravesical delivery system, versus intravesical chemotherapy in patients with intermediate-risk non–muscle-invasive bladder cancer with susceptible FGFR alterations.

    Advancements in genitourinary cancers are evolving rapidly, and it is often challenging for busy urologists and urologic oncologists to stay current with these emerging data, which can lead to suboptimal outcomes in their patients. In this activity, expert faculty assess key data in locally advanced prostate cancer and bladder cancer and best practices for the integration of these findings to clinical practice.

Facebook Comments

Schedule28 May 2024